3 completed, 2 withdrawn. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Withdrawn 2 |
Follow SS1(dsFv)PE38: new trials by email Literature Review of SS1(dsFv)PE38 trials Research Report on SS1(dsFv)PE38
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma SS1 (dsFv) PE38, Paclitaxel, Carboplatin - Non-Small Cell Lung Cancer, Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 2 | 2009-12-29 | 2017-07-02 |
| Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors SS1(dsFv)-PE38 immunotoxin - Cervical Cancer, Fallopian Tube Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 2003-07-01 | 2015-04-30 | |
| Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days SS1(dsFv)-PE38 - Neoplasms | Phase 1 | Withdrawn | INSYS Therapeutics Inc | 2001-02-01 | 2014-11-14 | |
| Immunotoxin Therapy in Treating Patients With Advanced Cancer SS1(dsFv)-PE38 immunotoxin - Cervical Cancer, Fallopian Tube Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 2000-12-01 | 2015-04-30 | |
| Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin - Neoplasms | Phase 1 | Withdrawn | INSYS Therapeutics Inc | 2000-11-01 | 2014-11-14 |
Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (3) · Brenner Tumor (2) · Carcinoma, Ovarian Epithelial (2) · Fallopian Tube Neoplasms (2) · Head and Neck Neoplasms (2) · Mesothelioma, Malignant (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Salivary Gland Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma (1)
National Cancer Institute (NCI) (3) · INSYS Therapeutics Inc (2)
United States (5)
Raffit Hassan, MD (1) · Robert Kreitman, MD (1)